Literature DB >> 34152054

Adjuvant Olaparib Improves Disease-Free Survival in Early, High-Risk, BRCA-Mutated, HER2- Breast Cancer.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34152054      PMCID: PMC8262311          DOI: 10.1002/onco.13863

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  4 in total

1.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

2.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

3.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Authors:  Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do-Youn Oh; Anke Reinacher-Schick; Giampaolo Tortora; Hana Algül; Eileen M O'Reilly; David McGuinness; Karen Y Cui; Katia Schlienger; Gershon Y Locker; Hedy L Kindler
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

4.  Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Maha Hussain; Joaquin Mateo; Karim Fizazi; Fred Saad; Neal Shore; Shahneen Sandhu; Kim N Chi; Oliver Sartor; Neeraj Agarwal; David Olmos; Antoine Thiery-Vuillemin; Przemyslaw Twardowski; Guilhem Roubaud; Mustafa Özgüroğlu; Jinyu Kang; Joseph Burgents; Christopher Gresty; Claire Corcoran; Carrie A Adelman; Johann de Bono
Journal:  N Engl J Med       Date:  2020-09-20       Impact factor: 91.245

  4 in total
  1 in total

1.  Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.

Authors:  Lieske H Schrijver; Thea M Mooij; Anouk Pijpe; Gabe S Sonke; Marian J E Mourits; Nadine Andrieu; Antonis C Antoniou; Douglas F Easton; Christoph Engel; David Goldgar; Esther M John; Karin Kast; Roger L Milne; Håkan Olsson; Kelly-Anne Phillips; Mary Beth Terry; John L Hopper; Flora E van Leeuwen; Matti A Rookus
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 13.506

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.